GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arch Biopartners Inc (TSXV:ARCH) » Definitions » Inventories, Raw Materials & Components

Arch Biopartners (TSXV:ARCH) Inventories, Raw Materials & Components : C$0.00 Mil (As of Mar. 2025)


View and export this data going back to 2000. Start your Free Trial

What is Arch Biopartners Inventories, Raw Materials & Components?

Arch Biopartners's inventories, raw materials & components for the quarter that ended in Mar. 2025 was C$0.00 Mil.


Arch Biopartners Inventories, Raw Materials & Components Historical Data

The historical data trend for Arch Biopartners's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Arch Biopartners Inventories, Raw Materials & Components Chart

Arch Biopartners Annual Data
Trend Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Arch Biopartners Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24 Dec24 Mar25
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Arch Biopartners Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.


Arch Biopartners Business Description

Industry
Traded in Other Exchanges
Address
545 King Street West, Toronto, ON, CAN, M5V 1M1
Arch Biopartners Inc is a late-stage clinical trial company focused on preventing acute kidney injury and organ damage caused by inflammation. The company is developing a platform of novel drugs that target the dipeptidase-1 (DPEP1) inflammation pathway, which is prevalent in the kidneys, lungs, and liver.